更新于：2024-12-07
Pinaverium bromide
匹维溴铵
更新于：2024-12-07
概要
基本信息
结构
分子式C26H41Br2NO4 |
InChIKeyIKGXLCMLVINENI-UHFFFAOYSA-M |
CAS号53251-94-8 |
关联
21
项与 匹维溴铵 相关的临床试验匹维溴铵片在中国健康受试者中餐后状态下的单剂量、随机、开放、四周期、两序列、完全重复交叉的生物等效性正式试验
匹维溴铵片在健康人群中的生物等效性试验
匹维溴铵片在健康受试者中随机、开放、单剂量、两制剂、重复交叉对照空腹及餐后状态下的生物等效性研究
100 项与 匹维溴铵 相关的临床结果
登录后查看更多信息
100 项与 匹维溴铵 相关的转化医学
登录后查看更多信息
100 项与 匹维溴铵 相关的专利（医药）
登录后查看更多信息
166
项与 匹维溴铵 相关的文献（医药）2024-11-01Cell Reports
A platform of functional studies of ESCC-associated gene mutations identifies the roles of TGFBR2 in ESCC progression and metastasis
Article
作者: Li, Yaxin ; Zhang, Mengsha ; Han, Zongkai ; Pan, Xiangyu ; Lin, Huahang ; Chen, Longqi ; Zhang, Shiyu ; Wang, Jian ; Na, Feifei ; Zhou, Jianfeng ; Zhong, Ailing ; Hu, Bing ; Chen, Xuelan ; Xiong, Xingyu ; Wang, Lu ; Liu, Yu ; Luo, Xiangmeng ; Li, Yuan ; Wan, Xudong ; Zou, Yang ; Lu, Runda ; Dai, Siqi ; Tan, Ping ; Chen, Chong ; Liu, Yixin ; Du, Jiajia ; Lu, Zhenghao ; Wu, Baohong ; Guo, Linjie ; Zhang, Qi ; Liu, Hongyu ; Wang, Yingjie ; Wang, Manli
Genomics studies have detected numerous genetic alterations in esophageal squamous cell carcinoma (ESCC). However, the functions of these mutations largely remain elusive, partially due to a lack of feasible animal models. Here, we report a convenient platform with CRISPR-Cas9-mediated introduction of genetic alterations and orthotopic transplantation to generate a series of primary ESCC models in mice. With this platform, we validate multiple frequently mutated genes, including EP300, FAT1/2/4, KMT2D, NOTCH2, and TGFBR2, as tumor-suppressor genes in ESCC. Among them, TGFBR2 loss dramatically promotes tumorigenesis and multi-organ metastasis. Paradoxically, TGFBR2 deficiency leads to Smad3 activation, and disruption of Smad3 partially restrains the progression of Tgfbr2-mutated tumors. Drug screening with tumor organoids identifies that pinaverium bromide represses Smad3 activity and restrains Tgfbr2-deficient ESCC. Our studies provide a highly efficient platform to investigate the in vivo functions of ESCC-associated mutations and develop potential treatments for this miserable malignancy.
2024-08-28IUCrData
Article
作者: Rousselin, Yoann ; Clavel, Alexandre
The structure of pinaverium bromide (systematic name: 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-{2-[2-(6,6-dimethyl-2-bicyclo[3.1.1]heptanyl)ethoxy]ethyl}morpholin-4-ium bromide; C26H41Br2NO4), was determined at 110 K. It has monoclinic (P21) symmetry. It is of interest with respect to its anti-inflammatory properties. The asymmetric unit contains two independent molecules, one of which exhibits disorder of the bicyclo terminal group (occupancy factors: 0.78 and 0.22).
2024-06-01ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
Acute exposure and biomarkers assessment in rainbow trout exposed to selected pharmaceuticals
Article
作者: André, C ; Gagné, F ; Auclair, J
Pharmaceuticals released from municipal effluents discharges pose a risk to aquatic organisms. The toxicity of 5 pharmaceuticals with distinct therapeutic actions were assessed in rainbow trout: olanzapine (antipsychotic), erythromycin (antibiotic), mycophenoate (immunosuppression), pinaverium (anti-inflammatory) and trazodone (sedative). Juveniles were exposed to these drugs for 96 h at concentrations between 64 µg/L up to 40 mg/L to reach lethality. Survival was determined and a suite of biomarkers was analyzed for drug biotransformation, oxidative stress/damage and metabolic activity at sublethal concentrations. The data revealed the following toxicity: olanzapine >trazodone>mycophenolate>pinaverium∼erythromycin based on mortality. The data also revealed that toxicity was associated to mass, pKa and hydrophobicity and the following sublethal effects: GST, LPO and DNA strand breaks. Pharmaceuticals with lower molecular weight, physiological pKa, moderate hydrophobicity, low biotransformation and DNA strand breaks were generally more toxic to fish. However, this should be considered as a general guide in identifying toxic pharmaceuticals in non-target organisms.
100 项与 匹维溴铵 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃痉挛 | 中国 | - | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脓毒症 | 临床前 | 中国 | 2024-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 蓋網顧網齋餘積築襯築(壓醖選遞選襯壓構繭鹹) = 構繭鬱鑰齋醖衊鹽糧壓 憲簾構艱鹹膚製遞壓觸 (網鑰糧糧鬱憲範鏇觸觸 ) | - | 2014-10-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用